Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

• Status: Completed
• Trial end date: 2021-02-07
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gannex Pharma Co., Ltd.
• Collaborator: Hunan Provincial People's Hospital

Criteria

Key Inclusion Criteria:

• 23kg/m2 ≤ BMI <40kg/m2.

Key Exclusion Criteria:

• A history of thyroid disease.

• A positive HBsAg, HCV Ab and/or HIV Ab.